Genmab and Lundbeck implement sustainability goals in executive incentive programs

Genmab and Lundbeck currently belong in the exclusive club of C25 companies that are integrating ESG indicators into their management incentive compensation plans.
Lundbeck CEO Deborah Dunsire | Photo: Gregers Tycho/ERH
Lundbeck CEO Deborah Dunsire | Photo: Gregers Tycho/ERH
BY ØKONOMISK UGEBREV, PROCESSED BY RITZAU, TRANSLATED BY NIELSINE NIELSEN

Prominent pharmaceutical industry figures like Jan van de Winkel and Deborah Dunsire from Genmab and Lundbeck, respectively, are joining top executives at Novo Nordisk and Novozymes in a small but exclusive club of C25 companies which integrate ESG indicators into their management incentive schemes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading